AzTrials
AzTrials

PainPhase 4IUDNCT02827487

Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion

A Phase 4 study testing Tramadol, Celecoxib and IUD in people with Pain, run by Cairo University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Two hundred and ten women requesting IUD insertion will be randomly divided into three equal groups. To ensure blinding the double dummy technique will be used in which group 1 will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally in addition to a placebo similar to Celecoxib, group 2 will receive… Read more about this study

Who is it for?
Ages 20 to 45 years, women only
Conditions the study is for
Pain
What is being tested?
Tramadol, Celecoxib and IUD
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
210 participants
Where
1 siteEgypt
Study dates
1 Jul 2016to 1 Jul 2020
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Women with expected difficult IUD insertion like nulliparous women and women with previous cesarean section.

Who cannot join

  • Previous vaginal delivery.
  • Submucous myoma.
  • Uterine anomalies.
  • Undiagnosed vaginal bleeding.
  • Pelvic inflammatory disease.

Trial locations and contacts

1 site in 1 country.

AbdelGany M Hassan, MRCOG, MD contact

1017801604

abdelgany2@gmail.com

Egypt1 site, 1 recruiting
  • Cairo University Hospitals

    Cairo

    AbdelGany MA Hassan, MRCOG, MD, 00217801604, abdelgany2@gmail.com

    AbdelGany MA Hassan, MRCOG, MD

    Recruiting

Other trials in Egypt

About this study

Official title: Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion: A Double Blind Placebo Controlled Trial

Two hundred and ten women requesting IUD insertion will be randomly divided into three equal groups. To ensure blinding the double dummy technique will be used in which group 1 will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally in addition to a placebo similar to Celecoxib, group 2 will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to Tramadol, and group 3 will received a placebo similar to Tramadol in addition to a placebo similar to Celecoxib. All the drugs will be given 2 hour before the procedure.

After insertion of the IUD the women's pain perception will be assessed using a visual analogue scale (VAS) graduated from zero to 10 with zero corresponding to no pain and 10 corresponding to the worst possible pain.

Read the detailed description

The intrauterine device (IUD) is a commonly used long-acting, effective and reversible method of contraception. IUD insertion is usually associated with a variable degree of pain. The majority of women experience mild pain or discomfort during IUD insertion, and some women may experience severe pain. Nulliparous women, women who delivered only by cesarean section and women remote from vaginal delivery are subgroups of women who experience more pain during IUD insertion. Prophylactic pharmacological interventions for management of pain associated with IUD insertion include nonsteroidal anti-inflammatory drugs (NSAIDs), opioid analgesics including Tramadol. Tramadol hydrochloride is an orally active centrally acting synthetic opioid. It is an atypical analgesic with a dual mechanism of action: serotonin and norepinephrine reuptake inhibition and modest l-opioid agonist. It has a lower incidence of respiratory depression, cardiac depression, side effects on smooth muscle and abuse potential as compared to typical opioid agents. Cervical ripening with prostaglandins was suggested facilitate the introduction of the IUD through the cervix, although at the cost of increased pain due to uterine cramping.

The study objective is to compare the effectiveness and side effects of oral Tramadol 100mg versus oral Celecoxib 200mg in reducing pain associated with operative outpatient hysteroscopy in an attempt to find the most effective drug with the least possible side effects to be used before IUD insertion.

Two hundred and ten women requesting IUD insertion will be randomly divided into three equal groups. To ensure blinding the double dummy technique will be used in which group 1 will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally in addition to a placebo similar to Celecoxib, group 2 will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to Tramadol, and group 3 will received a placebo similar to Tramadol in addition to a placebo similar to Celecoxib. All the drugs will be given 2 hour before the procedure. An independent person will generate the allocation sequence using computer generated random numbers.

The researchers will performed bimanual examination, introduce a speculum into the vagina and sterilized the cervix with povidone iodine before inserting the IUD according to the manufacturer recommendations.

After insertion of the IUD the women's pain perception will be assessed using a visual analogue scale (VAS) graduated from zero to 10 with zero corresponding to no pain and 10 corresponding to the worst possible pain.

Quantitative data will be statistically represented in terms of mean ± standard deviation (± SD) while categorical data will be represented as frequency and percentage. Comparison of quantitative data will be done using ANOVA test for independent samples while categorical data will be compared using Chi squared test or Fisher exact test when appropriate. A probability value (p value) less than 0.05 will be considered significant.

To the best of the investigators' knowledge this is the first trial to investigate the role of Celecoxib and oral Tramadol in reducing IUD insertion associated pain, with no previous data to calculate the sample size with. Assuming that the response will be normally distributed, the sample size is calculated to detect a mean difference of 1 unit between Tramadol and Celecoxib pain scores during the procedure (lower difference are not considered clinically relevant) using VAS assuming that the within group standard deviation will be 2. The investigators will need to study 64 cases in each group to be able to reject the null hypothesis that the population means of the Tramadol and Celecoxib are equal with probability (power) 0.8. The investigators added 6 cases to each arm accounting for any missing data and procedure failure ending in 70 cases in each group. The Type I error probability associated with this test of this null hypothesis is 0.05 using Student's t test for independent samples. Sample size calculation is done using Stats Direct statistical software version 2.7.2 for Windows, Stats Direct Ltd., Cheshire, UK.

Conditions
Pain
Being tested
Tramadol, Celecoxib, Placebo 1, Placebo 2, IUD
Medical subject headings
Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TramadolDrug

    Women will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally 2 hours before IUD insertion.

  • CelecoxibDrug

    Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.

  • Placebo 1Drug

    Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.

  • Placebo 2Drug

    Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.

  • IUDProcedure or surgery

    IUD insertion

Study groups in NCT02827487
Study groupRoleWhat they receive
TramadolActive comparatorWomen will receive oral Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) and an oral placebo similar to Celecoxib 2 hours before IUD insertion.
Receives: Drug: Tramadol; Drug: Placebo 2; Procedure: IUD
CelecoxibActive comparatorWomen will receive oral Celecoxib 200mg (Celebrex® 200, Pfizer, USA) and an oral placebo similar to Tramadol 2 hours before IUD insertion.
Receives: Drug: Celecoxib; Drug: Placebo 1; Procedure: IUD
Placebo 1Placebo comparatorWomen will receive a placebo similar to Tramadol and a placebo similar to Celecoxib orally 2 hours before IUD insertion.
Receives: Drug: Placebo 1; Drug: Placebo 2; Procedure: IUD

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain after IUD insertion

    Women will mark a point corresponding to their pain on a visual analogue scale

    Measured: one minute after IUD insertion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jul 2016 (estimated)
  2. Study start1 Jul 2016
  3. Primary completion1 Jul 2020 (estimated)
  4. Study completion1 Jul 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
210 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02827487
Sponsor's protocol ID
Celecoxib IUD
Acronym
IUD
Status last verified
Apr 2019
First submitted
3 Jul 2016
Last updated
8 Apr 2019
Results posted
No
Data monitoring committee
Yes

Publications

  • Hassan A, Wahba A, Haggag H. Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial. Hum Reprod. 2016 Jan;31(1):60-6. doi: 10.1093/humrep/dev291. Epub 2015 Nov 29.

    PubMed 26621854
  • Kass-Wolff JH, Fisher JE. Evidence-based pain management for endometrial biopsies and IUD insertions. Nurse Pract. 2014 Mar 13;39(3):43-50. doi: 10.1097/01.NPR.0000434094.19101.d1.

    PubMed 24535311
  • Scavuzzi A, Souza AS, Costa AA, Amorim MM. Misoprostol prior to inserting an intrauterine device in nulligravidas: a randomized clinical trial. Hum Reprod. 2013 Aug;28(8):2118-25. doi: 10.1093/humrep/det240. Epub 2013 Jun 5.

    PubMed 23739219

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Tramadol, Celecoxib and IUD in people with Pain, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 8 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact AbdelGany M Hassan, MRCOG, MD (1017801604, abdelgany2@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain after IUD insertion (time frame: one minute after IUD insertion). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02827487, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in